Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer

BACKGROUND. Human epidermal growth factor receptor (HER)-2 testing in patients with operable breast cancer is aimed at identifying candidates for adjuvant anti–HER-2 treatment. However, commonly defined “HER-2(−)” tumors express variable levels of the HER-2 protein, which can influence prognosis. We...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rossi, Valentina, Sarotto, Ivana, Maggiorotto, Furio, Berchialla, Paola, Kubatzki, Franziska, Tomasi, Nicoletta, Redana, Stefania, Martinello, Rossella, Valabrega, Giorgio, Aglietta, Massimo, Ponzone, Riccardo, Montemurro, Filippo
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2012
Soggetti:
Breast Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500362/
https://ncbi.nlm.nih.gov/pubmed/22951668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0194
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi